Immunovant, Inc. Profile Avatar - Palmy Investing

Immunovant, Inc.

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fra…
Biotechnology
US, New York [HQ]
IMVT/Financials
Segments · Problems · Premarket · Compliance

Segment Analysis

Segment Analysis
Revenue · By Business Segment
Not available for IMVT
Revenue · By Area
Not available for IMVT
End of IMVT's Analysis
CIK: 1764013 CUSIP: 45258J102 ISIN: US45258J1025 LEI: - UEI: -
Secondary Listings
IMVT has no secondary listings inside our databases.